Predictive Factors for Rheumatoid Arthritis Flare After Switching From Intravenous to Subcutaneous Formulation of Tocilizumab in Real-World Practice

BACKGROUND: To evaluate the incidence and related factors of rheumatoid arthritis (RA) flares after switching from intravenous tocilizumab (TCZ-IV) to subcutaneous tocilizumab (TCZ-SC) injection in stable RA patients. METHODS: We retrospectively evaluated the medical records of stable RA patients wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahn, Soo Min, Oh, Ji Seon, Heo, Hyun Mi, Hong, Seokchan, Lee, Chang-Keun, Yoo, Bin, Kim, Yong-Gil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Medical Sciences 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9062274/
https://www.ncbi.nlm.nih.gov/pubmed/35502504
http://dx.doi.org/10.3346/jkms.2022.37.e138

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9062274/
https://www.ncbi.nlm.nih.gov/pubmed/35502504
http://dx.doi.org/10.3346/jkms.2022.37.e138

Ejemplares similares